Nintedanib Shows Promise For Advanced Renal Cell Carcinoma
Post-hoc analysis suggested that nintedanib may have been particularly effective in patients with liver metastases at baseline, extending both PFS (8.4 vs 5.6 months) and OS (12.1 vs 8.2 months) compared with sunitinib.10/17/2015
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Kidney Cancer | Liver | Liver Cancer | Renal Cell Carcinoma | Urology & Nephrology